Abstract
Osteoarthritis is usually regarded as a localized disease whose optimal treatment is a therapy applied directly to the affected joint. Unfortunately, current local therapies such as repeated intraarticular injections or constant infusions are associated with a higher risk of infection. One way to overcome this would be to transfer substances made locally by cells within the joint. However, attempts using direct vector transfers or intraarticular injections of ex vivo modified cells could not achieve a sustained protein secretion over several months. Another method of delivering biological factors (i.e.growth hormones) intraarticularly is to transplant an artificial organ, capable of supporting the regeneration of natural cartilage, directly into the affected joint The main difficulty of having to produce bioactive factors over a long period of time is overcome by implanting a chamber-like system filled with either genetically modified cells or a drug-releasing matrix. This drug delivery system would be located at a peripheral site of the joint and could release substances directly into the joint cavity which would be transported via the synovial fluid and/or diffused to the chondrocytes or synoviocytes.
Keywords: Cartilage, osteoarthritis, therapy, drug delivery, artificial organ
Current Drug Delivery
Title: Artificial Organs: A New Option for Treating Osteoarthritis
Volume: 4 Issue: 1
Author(s): J. Stove, L. Lehmann, S. Fickert, T. Aigner and R. Brenner
Affiliation:
Keywords: Cartilage, osteoarthritis, therapy, drug delivery, artificial organ
Abstract: Osteoarthritis is usually regarded as a localized disease whose optimal treatment is a therapy applied directly to the affected joint. Unfortunately, current local therapies such as repeated intraarticular injections or constant infusions are associated with a higher risk of infection. One way to overcome this would be to transfer substances made locally by cells within the joint. However, attempts using direct vector transfers or intraarticular injections of ex vivo modified cells could not achieve a sustained protein secretion over several months. Another method of delivering biological factors (i.e.growth hormones) intraarticularly is to transplant an artificial organ, capable of supporting the regeneration of natural cartilage, directly into the affected joint The main difficulty of having to produce bioactive factors over a long period of time is overcome by implanting a chamber-like system filled with either genetically modified cells or a drug-releasing matrix. This drug delivery system would be located at a peripheral site of the joint and could release substances directly into the joint cavity which would be transported via the synovial fluid and/or diffused to the chondrocytes or synoviocytes.
Export Options
About this article
Cite this article as:
Stove J., Lehmann L., Fickert S., Aigner T. and Brenner R., Artificial Organs: A New Option for Treating Osteoarthritis, Current Drug Delivery 2007; 4 (1) . https://dx.doi.org/10.2174/156720107779314839
DOI https://dx.doi.org/10.2174/156720107779314839 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiation Therapy Plus Angiogenesis Inhibition with Bevacizumab: Rationale and Initial Experience
Reviews on Recent Clinical Trials Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry Metallodrug Conjugates with Steroids and Selective Estrogen Receptor Modulators (SERM)
Current Medicinal Chemistry Neovascular Age-related Macular Degeneration: Past, Present, and Future
Current Angiogenesis (Discontinued) A Review Exploring Therapeutic Worth of 1,3,4-Oxadiazole Tailored Compounds
Mini-Reviews in Medicinal Chemistry The Role of Oxazolidine Derivatives in the Treatment of Infectious and Chronic Diseases
Current Bioactive Compounds siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy Diabetes and Pancreas: Why So Difficult? Potential Mechanisms of Elevated Serum Pancreatic Enzymes
Current Medicinal Chemistry Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol Derivatives
Mini-Reviews in Medicinal Chemistry Molecular Dynamics in Esophageal Adenocarcinoma: Who’s in Control?
Current Cancer Drug Targets Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design Epivention: Epigenetic Based Cancer Chemoprevention
Epigenetic Diagnosis & Therapy (Discontinued) Editorial (Thematic Issue: Chemoinformatics Models for Pharmaceutical Design, Part 2)
Current Pharmaceutical Design HPLC Analysis of Human Pituitary Hormones for Pharmaceutical Applications
Current Pharmaceutical Analysis Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers
Clinical Cancer Drugs Meditation: A Review of its Use in Western Medicine and, in Particular, its Role in the Management of Sexual Dysfunction
Current Psychiatry Reviews Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer
Current Clinical Pharmacology Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Current Pharmaceutical Design Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets